- Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first halfBiopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $1…Endpoints · 17d ago↗ source
- MeiraGTx strikes royalty deal; Fore's 2023 Series D continuesPlus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...Endpoints · 17d ago↗ source
- Conquering Medicare's ACCESS programThere was so much excitement when CMS announced the ACCESS program. Finally, a way for digital health companies to make their mark on Medicare! A program that pays only if patients get better! Bu…